| 000 | 01186 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250516151949.0 | ||
| 264 | 0 | _c20140116 | |
| 008 | 201401s 0 0 eng d | ||
| 022 | _a1527-3350 | ||
| 024 | 7 |
_a10.1002/hep.26481 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBajaj, Jasmohan S | |
| 245 | 0 | 0 |
_aCognitive improvement after HCV eradication: Extending the benefits. _h[electronic resource] |
| 260 |
_bHepatology (Baltimore, Md.) _cAug 2013 |
||
| 300 |
_a480-2 p. _bdigital |
||
| 500 | _aPublication Type: Editorial; Comment | ||
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aCognition Disorders _xetiology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xcomplications |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPolyethylene Glycols _xtherapeutic use |
| 650 | 0 | 4 |
_aRecombinant Proteins _xtherapeutic use |
| 650 | 0 | 4 |
_aRibavirin _xtherapeutic use |
| 700 | 1 | _aForton, Daniel M | |
| 773 | 0 |
_tHepatology (Baltimore, Md.) _gvol. 58 _gno. 2 _gp. 480-2 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/hep.26481 _zAvailable from publisher's website |
| 999 |
_c22771154 _d22771154 |
||